Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats

被引:29
作者
Chen, Y
Luk, KDK
Cheung, KMC
Lu, WW
An, XM
Ng, SSM
Lin, MC
Kung, HF [1 ]
机构
[1] Qingdao Univ, Affiliated Hosp Med Coll, Dept Orthopaed, Qingdao, Peoples R China
[2] Univ Hong Kong, Fac Med, Dept Orthopaed Surg, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China
[4] Univ Hong Kong, Open Lab Chem Biol, Hong Kong, Hong Kong, Peoples R China
[5] Univ Hong Kong, Inst Mol Technol Drug Discovery, Hong Kong, Hong Kong, Peoples R China
关键词
gene therapy; bone morphogenetic protein-2; adeno-associated virus; adenovirus; bone;
D O I
10.1016/j.bbrc.2004.03.098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have previously shown that gene therapy using adeno-associated virus (AAV) carrying bone morphogenetic proteins (BMPs) is a promising strategy for new bone formation in vivo in SD rats. However, it had a relatively low transduction efficiency. We investigate here whether enhanced osteogenic activity can be achieved without eliciting a severe immune response, using a cocktail of AAV-BMP2 and adenovirus (Ad)-BMP2 as a vector system. The muscles of SD rats were injected with either AAV-BMP2, Ad-BMP2, or an AAV-BMP2/Ad-BMP2 cocktail, and the in vivo bone formation was determined at eight weeks post-injection. Radiographic examination demonstrated that the addition of a low level or Ad-BMP2 to AAV-BMP2 produced significantly higher new bone formation than the use of AAV-BMP2 alone. Histological and immunohistological analysis revealed an enlarged bone-forming area and a long-term BMP2 expression, without pronounced infiltration of lymphocytes. Our results provide the first evidence that the introduction of a low level of adenovirus in vivo in immunocompetent Subjects can greatly enhance AAV-mediated, gene transfer, without inducing severe immune responses. This cocktail vector system may offer an attractive way of improving the efficiency of AAV-based gene delivery. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:675 / 681
页数:7
相关论文
共 23 条
[1]   In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector [J].
Alden, TD ;
Pittman, DD ;
Hankins, GR ;
Beres, EJ ;
Engh, JA ;
Das, S ;
Hudson, SB ;
Kerns, KM ;
Kallmes, DF ;
Helm, GA .
HUMAN GENE THERAPY, 1999, 10 (13) :2245-2253
[2]   Localized, direct plasmid gene delivery in vivo:: prolonged therapy results in reproducible tissue regeneration [J].
Bonadio, J ;
Smiley, E ;
Patil, P ;
Goldstein, S .
NATURE MEDICINE, 1999, 5 (07) :753-759
[3]   Gene-enhanced tissue engineering: Applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene [J].
Breitbart, AS ;
Grande, DA ;
Mason, JM ;
Barcia, M ;
James, T ;
Grant, RT .
ANNALS OF PLASTIC SURGERY, 1999, 42 (05) :488-495
[4]  
Chen Y, 2001, J Orthop Sci, V6, P199, DOI 10.1007/s007760100072
[5]   Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors [J].
Chen, Y ;
Luk, KDK ;
Cheung, KMC ;
Xu, R ;
Lin, MC ;
Lu, WW ;
Leong, JCY ;
Kung, HF .
GENE THERAPY, 2003, 10 (16) :1345-1353
[6]   In vivo new bone formation by direct transfer of adenoviral-mediated bone morphogenetic protein-4 gene [J].
Chen, Y ;
Cheung, KMC ;
Kung, HF ;
Leong, JCY ;
Lu, WW ;
Luk, KDK .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 298 (01) :121-127
[7]   Stimulation of new bone formation by direct transfer of osteogenic plasmid genes [J].
Fang, JM ;
Zhu, YY ;
Smiley, E ;
Bonadio, J ;
Rouleau, JP ;
Goldstein, SA ;
McCauley, LK ;
Davidson, BL ;
Roessler, BJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) :5753-5758
[8]   Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors [J].
Ferrari, FK ;
Samulski, T ;
Shenk, T ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1996, 70 (05) :3227-3234
[9]   Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis [J].
Fisher, KJ ;
Gao, GP ;
Weitzman, MD ;
DeMatteo, R ;
Burda, JF ;
Wilson, JM .
JOURNAL OF VIROLOGY, 1996, 70 (01) :520-532
[10]  
FLOTTE TR, 1995, GENE THER, V2, P357